FZ007-119

FZ007-119 is a potent and highly selective small molecule inhibitor of Tyrosine Kinase 2 (TYK2), currently under clinical development by Guangzhou Fermion Technology for the treatment of moderate-to-severe plaque psoriasis. It functions as an allosteric inhibitor by binding to the regulatory pseudokinase (JH2) domain of TYK2, rather than the conserved orthosteric ATP-binding (JH1) domain. This mechanism allows for exceptional selectivity for TYK2 over other Janus kinase family members (JAK1, JAK2, and JAK3), thereby minimizing the risk of JAK-related adverse events such as myelosuppression, lipid elevations, or liver enzyme changes. By inhibiting TYK2, FZ007-119 disrupts the signaling of key pro-inflammatory cytokines, including interleukin-23 (IL-23), interleukin-12 (IL-12), and Type I interferons, which are central to the pathogenesis of psoriasis and other autoimmune conditions.